Targeting CD19 with genetically modified EBV-specific human T lymphocytes

C. Roessig, S. P. Scherer, A. Baer, J. Vormoor, C. M. Rooney, Malcolm Brenner, H. Juergens

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Human Epstein-Barr virus-specific T cells were genetically modified to express chimeric receptors specific for human CD19, which is expressed on the cell surface of most B cell malignancies. The receptor-modified EBV-specific T cells can be expanded and maintained long term in the presence of EBV-infected B cells. They recognize autologous EBV-infected targets through their conventional T cell receptor, and allogeneic EBV-infected targets and tumor targets through their chimeric receptor. They efficiently lyse both EBV and CD19-positive tumor targets in the absence of background cytotoxicity against CD19-negative targets. Donor-derived EBV-specific T cells expressing chimeric anti-tumor receptors may represent a source of effector cells that could be safely administered to leukemia patients to eradicate minimal residual disease after allogeneic bone marrow transplantation.

Original languageEnglish (US)
JournalAnnals of Hematology
Volume81
Issue numberSUPPL. 2
StatePublished - Dec 1 2002

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Targeting CD19 with genetically modified EBV-specific human T lymphocytes'. Together they form a unique fingerprint.

Cite this